Creative Medical Technology (NASDAQ:CELZ – Get Free Report) announced its earnings results on Friday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.16), FiscalAI reports.
Creative Medical Technology Price Performance
Shares of Creative Medical Technology stock traded up $0.02 on Friday, reaching $0.62. The company had a trading volume of 106,318 shares, compared to its average volume of 107,754. The firm’s 50-day moving average price is $0.87 and its two-hundred day moving average price is $1.54. Creative Medical Technology has a 1 year low of $0.59 and a 1 year high of $4.72.
Analyst Upgrades and Downgrades
CELZ has been the subject of a number of analyst reports. Weiss Ratings cut shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. Roth Capital reissued a “buy” rating on shares of Creative Medical Technology in a report on Thursday, August 20th. Finally, Wall Street Zen raised Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.
View Our Latest Stock Report on CELZ
About Creative Medical Technology
Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.
The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.
Featured Stories
- Five stocks we like better than Creative Medical Technology
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
